New automated, closed system for cell therapy formulation and filling (APAC)

Wednesday 09:30 IST / 12:00 AWST / 13:00 KST / 13:00 JST / 14:00 AEST / 16:00 NZST

Sponsor

New automated, closed system for cell therapy formulation and filling (APAC)

Cell therapy manufacturing is rapidly evolving as more engineered cell therapies such as CAR-T, CAR-NK, and iPSC-derived therapies progress toward clinical and commercial production. However, many workflows still rely on multiple manual unit operations, which can introduce variability, contamination risk, and challenges in maintaining consistent product quality. In particular, two of the final steps in the cell therapy manufacturing process – formulation and filling – have traditionally suffered from a lack of fit-for-purpose technological innovation.

This webinar will examine the application of the Gibco™ CTS™ Compleo™ Fill and Finish System, an innovative automated formulation and filling technology, which helps reduce the risks associated with manual formulation and filling in cell therapy manufacturing. Real-world experimental data will be presented demonstrating phenotype preservation and volumetric accuracy across multiple dispensing volumes and engineered cell types. We will also discuss how the integration of the Gibco™ CTS™ Rotea™ Cell Processing System with the CTS™ Compleo™ system can streamline cell processing, formulation, and filling workflows, improve reproducibility and support scalable manufacturing, while maintaining critical cell quality attributes.

Attend this webinar for:

Performance characterization data showing ≤10% deviation from target volume across fill volumes ranging from sub-milliliter to large-volume outputs
Guidance on evaluating cell quality attributes before and after automated formulation and filling
Real-world examples of applying the workflow across multiple engineered cell types used in cell therapy products
Practical considerations for selecting and integrating modular, automated cell processing, formulation, and filling platforms capable of supporting multiple dose volumes
Assistance in planning scalable workflows for clinical and commercial cell therapy manufacturing

Young Kim

Scientist at Thermo Fisher Scientific

Dr Young Kim is a Scientist in Cell and Gene Therapy R&D at Thermo Fisher Scientific, where he focuses on developing automated workflows and instrumentation for advanced cell therapy manufacturing. His work centers on integrating cell processing, formulation, and filling technologies to support scalable, closed-system manufacturing of engineered cell therapies. Young holds a PhD in Neuroscience from the University of Southern California and has extensive experience in cellular biology, immunology, and translational research.

In 61 Days

You have registered for this webinar